RxDoctor Payments Data

James Nichols, MD

Family Medicine · Phoenix, AZNPI 1497746630

Payments from drug & device makers

$576in general payments, 2019–2025

Across 30 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$162
  • Lilly USA, LLC$109
  • AbbVie$83
  • Exact Sciences$74
  • AstraZeneca$53
  • Pfizer$20
  • plus $74 from 4 others

What the payments were for

  • Food & beverage$576100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott7$162
Lilly USA, LLC6$109
AbbVie4$83
Exact Sciences4$74
AstraZeneca4$53
Pfizer1$20
Astellas Pharma US Inc1$19
Novartis1$19
Novo Nordisk1$18
Analog Devices Inc.1$18

How this compares

$576 in reported general payments places this provider in the 60th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$376,213
Medicare patients
587
Services billed
13,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide103$107,540
JardianceEmpagliflozin66$66,351
EliquisApixaban61$61,398
OzempicSemaglutide37$41,952
XareltoRivaroxaban23$29,818
FarxigaDapagliflozin Propanediol31$25,592
JanuviaSitagliptin Phosphate23$20,473
MyrbetriqMirabegron24$12,814
InvokanaCanagliflozin17$10,120
LinzessLinaclotide12$9,763
Praluent PenAlirocumab17$8,491
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/711$6,179
Olmesartan Medoxomil156$3,795
Atorvastatin Calcium426$3,524
Pantoprazole Sodium232$2,807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$109$107,540103 claims
PfizerEliquis$20$61,39861 claims
Novo NordiskOzempic$18$41,95237 claims
AstraZenecaFarxiga$53$25,59231 claims
Astellas Pharma US IncMyrbetriq$19$12,81424 claims
AbbVieLinzess, Synthroid$83$10,79426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →